Want to see MGNX full AI Analyst Report?
MGNX Stock Chart & Stats
$4.04
$0.21(5.68%)
At close: 4:00 PM EDT
$4.04
$0.21(5.68%)
Day’s Range― - ―
52-Week Range$1.29 - $5.08
Previous CloseN/A
Volume200.74K
Average Volume (3M)585.38K
Market Cap
$280.28M
Enterprise Value$318.75
Total Cash (Recent Filing)$173.31M
Total Debt (Recent Filing)$35.09M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 04, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding63,700,188
10 Day Avg. Volume429,505
30 Day Avg. Volume585,375
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.83
Price to Sales (P/S)0.68
P/FCF Ratio-1.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside73.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$117.49M
Bulls Say, Bears Say
Bulls Say
Revenue Improvement And Reduced LossesHigher revenue and materially narrower losses indicate improving operating discipline or business mix. Although MacroGenics remains unprofitable, sustained progress toward breakeven could strengthen financial resilience if growth continues.
MGC026 Clinical AdvancementAdvancement into Stage 2 provides clinical validation for MGC026 and increases the pipeline’s long-term commercial potential. Further development could improve partnering prospects, though regulatory and efficacy risks remain.
Asset-light Operating ModelSelling manufacturing assets reduces operational intensity and shifts resources toward research and development. The supply agreement preserves production access while potentially improving capital efficiency and management focus on pipeline advancement.
Bears Say
Persistent Cash Burn And Funding DependenceNegative operating and free cash flow means the business is not yet self-funding. Continued cash consumption may require additional financing or partnering proceeds, creating dilution, execution, and funding risks over the medium term.
Unprofitable Operating ModelDespite improved margins, negative EBIT and EBITDA show that core operations have not reached sustainable profitability. Ongoing losses limit financial flexibility and make results dependent on pipeline progress, milestones, or other external funding.
Early-stage Clinical And Partnership DependenceThe company’s value creation remains tied to early clinical programs and collaboration economics rather than a broad commercial product base. Delays, trial failures, or weak partner execution could materially reduce future revenue opportunities.
MacroGenics News
MGNX FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $1.29 and its highest was $5.08 in the past 12 months.
What is MacroGenics’s market cap?
MacroGenics’s market cap is $280.28M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Nov 04, 2026 which is in 59 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Aug 13, 2026. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.388.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.32.
How many shares outstanding does MacroGenics have?
MacroGenics has 63,700,188 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of $0.31 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went up 3.431%.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in MGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (73.27% Upside)
$7.00 (73.27% Upside)
Blogger Sentiment
Neutral
MGNX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 36.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MacroGenics
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MGNX Stock 12 Month Forecast
Average Price Target
$7.00
▲(73.27% Upside)
Technical Analysis
Ownership Overview
2.60% Insiders
12.13% Mutual Funds
21.48% Other Institutional Investors
53.62% Public Companies and
Individual Investors